ees Europe: Battery Storage – Powerbanks for the Energy Transition
4.6.2024 15:49:00 EEST | Business Wire | Press release
Battery storage is booming. According to a study by Frontier Economics, the volume of grid-connected storage in Germany alone could increase to 60 gigawatts (GW) or 271 gigawatt-hours (GWh) by 2050. This is forty times the current storage capacity. Similar dynamics in cost reduction and installation speed are expected as seen with photovoltaics (PV) in recent years. Soon, battery storage will fundamentally change energy supply. The latest technologies, trends, and market developments will be showcased at ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems. It will take place from June 19 to 21 as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry, in Munich. Around 3,000 exhibitors and over 115,000 visitors from around the world are expected in 19 exhibition halls and an outdoor area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604806032/en/
Innovations in the field of large-scale storage can be seen at this year’s ees Europe. (Photo: Business Wire)
The growth of grid-connected storage brings enormous advantages to the energy system and offers economic benefits. The expansion of large-scale storage can significantly reduce the need for new gas power plant investments in Germany by up to 9 GW. This expansion also contributes significantly to reducing CO2 emissions. The key point: this growth is purely market-driven and does not rely on government subsidies.
Short-term storage enables system transformation
Battery storage increasingly assumes critical roles in ensuring a reliable power supply and stabilizing power grids. Large battery storage systems ensure voltage control, provide immediate reserve capacity, and facilitate black start capability, playing a part in congestion management. They can balance fluctuations in the grid within seconds and store energy for hours or days. The black start capability of storage systems is crucial in emergencies.
Moreover, storage systems can mitigate the effects of delayed grid expansion. They help optimize the utilization of the limited grid infrastructure, allowing more facilities to be connected. This enables more capacity and additional PV installations despite limited grid connection capacity. Another benefit: battery storage increases the market value of renewable energy. Green electricity can be stored when market prices are low and fed into the grid when demand is high and electricity prices are correspondingly high.
International storage revolution
Worldwide, exponential growth in battery storage is evident. Experts predict that global production capacity will rise to 500 GWh per year by 2025. In markets such as Australia, the USA, and India, tenders for new wind or solar capacities have been coupled with storage for years. In Germany, the speed of expansion and the installed storage capacity are still modest. However, this year, battery storage systems in Germany will surpass pumped storage systems in installed capacity for the first time.
Setting the right framework
To make stationary storage of all sizes attractive, a favorable market environment and simple regulations are needed. Market-driven expansion must continue to be enabled and improved. Modern framework conditions for battery storage should be set through reforms in grid fees, flexible electricity tariffs, or the introduction of contracts for difference.
ees Europe
Every year, ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, provides a networking opportunity for the industry’s key players – all under the motto “Innovating Energy Storage”. It focuses on the latest technologies, trends and market developments. ees Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.
For more information: www.ees-europe.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604806032/en/
Contact information
ressourcenmangel an der Panke GmbH
Roberto Freiberger
roberto.freiberger@ressourcenmangel.de
Solar Promotion GmbH
Peggy Zilay
zilay@solarpromotion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom